Insights

Gathering insights about Oncotelic…

Similar companies to Oncotelic

Oncotelic Tech Stack

Oncotelic uses 8 technology products and services including Amazon S3, WordPress, MySQL, and more. Explore Oncotelic's tech stack below.

Amazon S3
Content Delivery Network
WordPress
Content Management System
MySQL
Database
oEmbed
Dev Tools
WooCommerce
E-commerce
Font Awesome
Font Scripts
DataTables
Javascript Libraries
Google Tag Manager
Tag Management

Media & News

Oncotelic Therapeutics Details PDAOAI Platform and Opens Access to Its Total TGF-β Knowledge Corpus
AGOURA HILLS, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), a leader in RNA-based therapeutics, announced today opened access to PDAOAI, its proprietary evidence-interrogation platform designed to extract biologically meaningful signals from large, complex biomedical datasets without training bespoke large language models (LLMs) on proprietary data.
Dec 22, 2025 | www.globenewswire.com
Oncotelic Therapeutics and Brush and Key Foundation Announce Publication in International Journal of Molecular Sciences Highlighting Context-Dependent Biomarkers in Liver and Pancreatic Cancer
AGOURA HILLS, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) in collaboration with the Brush and Key Foundation, today announced the publication of a peer-reviewed research article in the International Journal of Molecular Sciences titled “Comparative Tumor Microenvironment Analysis for HCC and PDAC Using KMplotter.” Chang, W.-H.; Shah, D.; Myers, S.; Potts, M.; Qazi, S.; Trieu, V. International Journal of Molecular Sciences 2025, 26, 11920.
Dec 15, 2025 | www.globenewswire.com
Oncotelic and Sapu Nano Announce DeciparticleTM Led Biomarker Framework Identifying Tumors Most Likely to Respond to IV Sapu003, an Intravenous Everolimus Nanomedicine
AGOURA HILLS, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% owned Joint Venture, Sapu Nano today announced new biomarker data identifying a molecular signature that predicts sensitivity to Sapu003, the company's intravenous Deciparticle™ formulation of everolimus.
Dec 04, 2025 | www.globenewswire.com
Oncotelic and Sapu Nano Announces New PK Data Demonstrating IV Sapu003 Reduces GI Accumulation of Everolimus up to 67-Fold Compared With Oral Dosing
AGOURA HILLS, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% owned Joint Venture, Sapu Nano today announced new pharmacokinetic (PK) and tissue-distribution results demonstrating that Sapu003, the company's intravenous (IV) Deciparticle™ formulation of everolimus, substantially reduces gastrointestinal (GI) drug accumulation, addressing one of the most significant and well-recognized limitations of oral everolimus (Afinitor®).
Dec 03, 2025 | www.globenewswire.com
Oncotelic and Sapu Nano Unveils Broad-Applicability Deciparticle™ Nanomedicine Platform Capable of Formulating Multiple Hydrophobic Peptide, Macrolide, and Polyketide Drugs
AGOURA HILLS, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% owned Joint Venture, Sapu Nano, a clinical-stage nanomedicine company, today announced new data demonstrating that its proprietary Deciparticle ™ platform enables broad and consistent formulation of structurally diverse hydrophobic therapeutics—including macrolide mTOR inhibitors, cyclic peptides, linear peptides, ascomycin macrolactams, and polyketides—while maintaining a precise sub-20 nm nanoparticle profile suitable for intravenous (IV) delivery.
Dec 02, 2025 | www.globenewswire.com
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Anticipates Major Fair-Value Uptick Following New Independent JV Valuation
NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- via BioMedWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork ), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “Biotech Valuations Rise as New Clinical Platforms Show Progress,” please visit: https://ibn.fm/adoXU As advanced biotech programs move closer to commercialization, fair-value adjustments under U.S. Generally Accepted Accounting Principles (GAAP) are increasingly recognized as meaningful signals of real scientific and business advancement.
Nov 25, 2025 | www.globenewswire.com
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Emerging as Leader with New Independent JV Valuation
NEW YORK, Nov. 21, 2025 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
Nov 21, 2025 | www.globenewswire.com

Oncotelic's Email Address Formats

Oncotelic uses at least 1 format(s):

Oncotelic Email Formats	Example	Percentage
First.Last@oncotelic.com	John.Doe@oncotelic.com	38%
FLast@oncotelic.com	JDoe@oncotelic.com	22%
Last@oncotelic.com	Doe@oncotelic.com	3%
First.Last@oncotelic.com	John.Doe@oncotelic.com	37%

Frequently Asked Questions

What is Oncotelic's stock symbol?

Oncotelic is a publicly traded company; the company's stock symbol is OTLC.

What is Oncotelic's official website and social media links?

Oncotelic's official website is oncotelic.com and has social profiles on LinkedIn Crunchbase.

What is Oncotelic's SIC code NAICS code?

Oncotelic's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Oncotelic have currently?

As of December 2025, Oncotelic has approximately 23 employees across 2 continents, including North AmericaEurope. Key team members include Bioinformatic Specialist: S. Q.Attorney At Law: T. L.. Explore Oncotelic's employee directory with LeadIQ.

What industry does Oncotelic belong to?

Oncotelic operates in the Biotechnology Research industry.

What technology does Oncotelic use?

Oncotelic's tech stack includes Amazon S3WordPressMySQLoEmbedWooCommerceFont AwesomeDataTablesGoogle Tag Manager.

What is Oncotelic's email format?

Oncotelic's email format typically follows the pattern of First.Last@oncotelic.com. Find more Oncotelic email formats with LeadIQ.

Oncotelic

Q: What is Oncotelic's official website and social media links?

Oncotelic's official website is oncotelic.com. Oncotelic has social profiles on LinkedIn.

Q: How many employees does Oncotelic have currently?

Oncotelic has approximately 23 employees.

Q: What technology does Oncotelic use?

Oncotelic's tech stack includes RSS, jQuery, Yoast SEO, Apache HTTP Server, DataTables.

Biotechnology ResearchCalifornia, United States11-50 Employees

Oncotelic /Mateon is a convergent of PointR AI clustercomputing, Oncotelic antisense platform, and Mateon vascular disrupting agent.  Lead asset OT-101 is an antisense against TGF-beta for cancer, covid-19, and other viruses

Company Overview

Website: oncotelic.com
SIC Code: 8733 - Noncommercial Research Organizations
Stock Symbol: OTLC
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees: 11-50

Media & News

Funding & Financials

$1M$10M
Oncotelic's revenue is estimated to be in the range of $1M$10M

Funding & Financials

$1M$10M
Oncotelic's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Oncotelic

IO Biotech

Harpoon Therapeutics

Immatics

SomaLogic

Agenus

Immunocore

Turnstone Biologics

Oxford Biomedica

Oncotelic Tech Stack

Media & News

Oncotelic Therapeutics Details PDAOAI Platform and Opens Access to Its Total TGF-β Knowledge Corpus

Oncotelic Therapeutics and Brush and Key Foundation Announce Publication in International Journal of Molecular Sciences Highlighting Context-Dependent Biomarkers in Liver and Pancreatic Cancer

Oncotelic and Sapu Nano Announce DeciparticleTM Led Biomarker Framework Identifying Tumors Most Likely to Respond to IV Sapu003, an Intravenous Everolimus Nanomedicine

Oncotelic and Sapu Nano Announces New PK Data Demonstrating IV Sapu003 Reduces GI Accumulation of Everolimus up to 67-Fold Compared With Oral Dosing

Oncotelic and Sapu Nano Unveils Broad-Applicability Deciparticle™ Nanomedicine Platform Capable of Formulating Multiple Hydrophobic Peptide, Macrolide, and Polyketide Drugs

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Anticipates Major Fair-Value Uptick Following New Independent JV Valuation

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Emerging as Leader with New Independent JV Valuation

Oncotelic's Email Address Formats

Frequently Asked Questions

What is Oncotelic's stock symbol?

What is Oncotelic's official website and social media links?

What is Oncotelic's SIC code NAICS code?

How many employees does Oncotelic have currently?

What industry does Oncotelic belong to?

What technology does Oncotelic use?

What is Oncotelic's email format?

Oncotelic

Company Overview

Media & News

Oncotelic Therapeutics Details PDAOAI Platform and Opens Access to Its Total TGF-β Knowledge Corpus

Oncotelic Therapeutics and Brush and Key Foundation Announce Publication in International Journal of Molecular Sciences Highlighting Context-Dependent Biomarkers in Liver and Pancreatic Cancer

Oncotelic and Sapu Nano Announce DeciparticleTM Led Biomarker Framework Identifying Tumors Most Likely to Respond to IV Sapu003, an Intravenous Everolimus Nanomedicine

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?